Cover Image
市場調查報告書

肌肉內藥物遞輸市場與開發平台分析

Intramuscular Drug Delivery Market & Pipeline Insight

出版商 PNS Pharma 商品編碼 323304
出版日期 內容資訊 英文 900 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
肌肉內藥物遞輸市場與開發平台分析 Intramuscular Drug Delivery Market & Pipeline Insight
出版日期: 2015年01月23日 內容資訊: 英文 900 Pages
簡介

肌肉內藥物遞輸(藥物輸送)的研究、開發,這數十年達成了製藥產業上的大躍進。透過高全性和有效性資料的精通,成為該領域上大規模投資的重要要素。

本報告提供肌肉內藥物遞輸市場相關調查分析、機制、市場預測、開發平台、上市產品、未來發展預測等相關的系統性資訊。

第1章 所謂肌肉內藥物遞輸

第2章 各種藥物遞輸機制概要

第3章 肌肉內藥物遞輸機制

  • 機制概要
  • 肌肉內藥物遞輸設備

第4章 全球肌肉內藥物遞輸的市場預測

  • 市場概要
  • 肌肉內藥物遞輸的開發平台概要

第5章 全球肌肉內藥物遞輸的市場動態

  • 良好的市場參數
  • 課題

第6章 肌肉內藥物遞輸市場未來發展預測

第7章 肌肉內給藥藥品的開發平台:各企業、各國、各適應症、各階段

  • 研究
  • 前臨床
  • 臨床
  • 階段0
  • 階段I
  • 階段I/II
  • 階段II
  • 階段II/III
  • 階段III
  • 預登記
  • 登記完畢

第8章 已上市肌肉內給藥藥品:各企業、各國、各適應症

第9章 臨床實驗平台的中止、暫停中的肌肉內給藥藥品

  • 未開發
  • 中止
  • 撤出市場
  • 暫停中

第10章 競爭情形

  • Antares Pharma
  • Eli Lily
  • Galaxo
  • HMD pharmaceuticals
  • Inovio Pharmaceuticals
  • Merck
  • Novartis
  • Pacira Pharmaceuticals
  • Pfizer
  • Pharmajet
  • Teva Pharmaceutical

圖表

目錄

The research and development of intramuscular drug delivery has gained significant momentum in pharmaceutical industry during past several decades. The high safety and efficacy profiles and familiarity are the most important factor for large investments in this segment. Owing to large past experience and their usage in public programs they have wide acceptance among patients due which their market is expected to be safe for investments. Pharmaceutical companies focused their efforts to churn the market by investing more funds in research and development activities. As a result, newer therapeutics are entering in global market and others are at various phases of clinical trials which are expected to enter in market in near future.

Intramuscular drug delivery market contains therapeutics belonging to different disease indication, mechanism of action and drug delivery devices. The higher sales will depend upon efficacy of newly developed intramuscular drug and marketing strategy to drive its sales. They are used for first-line therapy which they are expected to remain due to their proven pharmacological performance. The large number of patient population is expected to help the pharmaceutical companies in investigating innovative drugs during clinical trials but their market introduction will take some time before gaining success in global market.

Novel technologies are required to develop intramuscular drug delivery including both drug molecule and delivery devices. In addition to these features, new principles have to be found in coming years because most of the presently available intramuscular drug delivery systems are based on old foundations. These factors may work for many disease indications without change for several years but in case of infectious disease, oncology and autoimmune diseases novelty is required. Change in scenario is expected to have multiple effects on drug discovery and development technology along with decreasing the mortality rates. Despite variety in formulations and disease indication, stagnancy will cause severe damage to progress of global intramuscular drug delivery market.

Intramuscular drug delivery methods using molecular structures and polymers are expected to gain momentum in coming years. More structural, physical and biochemical improvements have to take place to increase their marketing potential. Underlying principles behind these materials are being discovered to increase their pharmacological benefits for future usage. Gels are another material required for future development better and efficient delivery of intramuscular drug to the patients. The capabilities of sustained release have been found to be associated with these materials which are expected to make sustainable market place in near future. Researchers are developing new materials with better biodegradability and sustained release capabilities for providing efficient intramuscular drug delivery.

With the recent technological advances, it is expected that newer methods for intramuscular drug delivery will be developed and commercialized in coming years. Market size of these materials and methods is modest which is expected to steady growth but before doing so they have to improve a lot before becoming marketable. Many novel intramuscular drugs are at various phases of clinical trials which are expected to be available after some time. Pharmaceutical companies have already identified the opportunities involved in the development of intramuscular drugs and many of them are at advanced phases of clinical trials. They are supposed to be cost effective along with pharmacologically efficient and minimized side effects.

"Intramuscular Drug Delivery Market & Pipeline Insight" Report Findings:

  • Intramuscular Drug Delivery Mechanism
  • Global Intramuscular Drug Delivery Market Outlook
  • Intramuscular Drug Pipeline by Company, Country, Indication & Phase
  • Intramuscular Drug Pipeline: 364 Drugs
  • Marketed Intramuscular Drugs: 186 Drugs
  • Majority Drugs in Phase-I Trials:108
  • Global Intramuscular Drug Delivery Market Future Prospects

Table of Contents

1. Introduction to Intramuscular Drug Delivery

2. Overview of Different Drug Delivery Mechanisms

3. Intramuscular Drug Delivery Mechanism

  • 3.1 Mechanism Overview
  • 3.2 Intramuscular Drug Delivery Devices

4. Global Intramuscular Drug Delivery Market Outlook

  • 4.1 Market Overview
  • 4.2 Intramuscular Drug Delivery Pipeline Overview

5. Global Intramuscular Drug Delivery Market Dynamics

  • 5.1 Favorable Market Parameters
  • 5.2 Challenges

6. Intramuscular Drug Delivery Market Future Prospects

7. Intramuscular Drug Pipeline by Company, Country, Indication & Phase

  • 7.1 Research
  • 7.2 Preclinical
  • 7.3 Clinical
  • 7.4 Phase-0
  • 7.5 Phase-I
  • 7.6 Phase-I/II
  • 7.7 Phase-II
  • 7.8 Phase-II/III
  • 7.9 Phase-III
  • 7.10 Preregistration
  • 7.11 Registered

8. Marketed Intramuscular Drugs by Company, Country & Indication

9. Discontinued & Suspended Intramuscular Drugs in Clinical Pipeline

  • 9.1 No Development Reported
  • 9.2 Discontinued
  • 9.3 Market Withdrawal
  • 9.4 Suspended

10. Competitive Landscape

  • 10.1 Antares Pharma
  • 10.2 Eli Lily
  • 10.3 Galaxo
  • 10.4 HMD pharmaceuticals
  • 10.5 Inovio Pharmaceuticals
  • 10.6 Merck
  • 10.7 Novartis
  • 10.8 Pacira Pharmaceuticals
  • 10.9 Pfizer
  • 10.10 Pharmajet
  • 10.11 Teva Pharmaceutical
  • Figure 1-1: Site of Intramuscular Drug Delivery
  • Figure 1-2: Various Methods of Drug Delivery
  • Figure 1-3: Features of Intramuscular Drug Delivery System
  • Figure 1-4: Classification of Human Muscular System
  • Figure 1-5: Intramuscular Drug Delivery Sites for Administration
  • Figure 1-6: Technical Issues with Intramuscular Drug Delivery
  • Figure 3-1: Factors Affecting Intramuscular Drug Activity
  • Figure 3-2: Mechanism of Intramuscular Drug Delivery
  • Figure 3-3: Properties of Intramuscular Drug Delivery
  • Figure 4-1: Intramuscular Pipeline by Phase (%), 2015
  • Figure 4-2: Intramuscular Pipeline by Phase (Numbers), 2015
  • Figure 4-3: No Development Reported Intramuscular Pipeline by Phase (%), 2015
  • Figure 4-4: No Development Reported Intramuscular Pipeline by Phase (Numbers), 2015
  • Figure 4-5: Discontinued Intramuscular Pipeline by Phase (%), 2015
  • Figure 4-6: Discontinued Intramuscular Pipeline by Phase (Numbers), 2015
  • Figure 4-7: Suspended Intramuscular Pipeline by Phase (%), 2015
  • Figure 4-8: Suspended Intramuscular Pipeline by Phase (Numbers), 2015
  • Figure 5-1: Drivers for Intramuscular Drug Delivery Market
  • Figure 5-2: Challenges for Intramuscular Drug Delivery
  • Table 2-1: Overview of Different Drug Delivery Mechanisms
  • Table 3-1: Comparative Analysis of Intramuscular Drug Delivery Devices
Back to Top